Literature DB >> 29441525

Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative.

J Kottner1, L Jacobi2, E Hahnel1, M Alam3, K Balzer4, D Beeckman5, C Busard6, J Chalmers7, S Deckert2, V Eleftheriadou7, K Furlan3, S E R Horbach6, J Kirkham8, A Nast1, P Spuls6, D Thiboutot9, L Thorlacius10, K Weller1, H C Williams7, J Schmitt2.   

Abstract

Results of clinical trials are the most important information source for generating external clinical evidence. The use of different outcomes across trials, which investigate similar interventions for similar patient groups, significantly limits the interpretation, comparability and clinical application of trial results. Core outcome sets (COSs) aim to overcome this limitation. A COS is an agreed standardized collection of outcomes that should be measured and reported in all clinical trials for a specific clinical condition. The Core Outcome Set Initiative within the Cochrane Skin Group (CSG-COUSIN) supports the development of core outcomes in dermatology. In the second CSG-COUSIN meeting held in 2017, 11 COS development groups working on skin diseases presented their current work. The presentations and discussions identified the following overarching methodological challenges for COS development in dermatology: it is not always easy to define the disease focus of a COS; the optimal method for outcome domain identification and level of detail needed to specify such domains is challenging to many; decision rules within Delphi surveys need to be improved; appropriate ways of patient involvement are not always clear. In addition, there appear to be outcome domains that may be relevant as potential core outcome domains for the majority of skin diseases. The close collaboration between methodologists in the Core Outcome Set Initiative and the international Cochrane Skin Group has major advantages for trialists, systematic reviewers and COS developers.
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2018        PMID: 29441525     DOI: 10.1111/bjd.16324

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  2 in total

1.  Development of international clinical practice guidelines: benefits, limitations, and alternative forms of international collaboration.

Authors:  Murad Alam; Vishnu Harikumar; Bianca Y Kang; Sarah A Ibrahim; Nour Kibbi; Joshua L Owen; Ian A Maher; Todd V Cartee; Joseph F Sobanko; Kelly A Reynolds; Diana Bolotin; Abigail H Waldman; Kira Minkis; Brian Petersen; M Laurin Council; Kishwer S Nehal; Y Gloria Xu; S Brian Jiang; Ally-Khan Somani; Christopher K Bichakjian; Conway C Huang; Daniel B Eisen; David M Ozog; Erica H Lee; Faramarz H Samie; Isaac M Neuhaus; Jeremy S Bordeaux; Jordan V Wang; Justin J Leitenberger; Margaret W Mann; Naomi Lawrence; Nathalie C Zeitouni; Nicholas Golda; Ramona Behshad; Sherrif F Ibrahim; Siegrid S Yu; Thuzar M Shin; William G Stebbins; Brandon Worley
Journal:  Arch Dermatol Res       Date:  2020-11-20       Impact factor: 3.017

2.  A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.

Authors:  Francisco Gómez-García; Pedro Jesús Gómez-Arias; Ana Montilla-López; Jorge Hernández-Parada; Juan Luís Sanz-Cabanillas; Juan Ruano; Esmeralda Parra-Peralbo
Journal:  Front Med (Lausanne)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.